We are thrilled to announce that our team will be participating in the PSI 2024 Conference, which will take place from Sunday, June 16th to Wednesday, June 19th at the Beurs van Berlage in Amsterdam, Netherlands.
The PSI Conference is a premier event for statisticians and quantitative scientists involved in drug development and healthcare. This year’s conference is expected to draw between 350 and 450 experts from industry, academia, and regulatory agencies worldwide.
The conference will span three days, offering a broad program filled with plenary and parallel sessions, breakout discussions, workshops, and a poster session. For this last one, our colleagues Maarten van Dijk, Seyma Öztürk, Stephan Bischofberger and Hannes Buchner have prepared a poster as a joint work between them, and it will be presented by Managing Director Hannes Buchner. The poster contains a systematic review for which data from all recently published Phase III oncology trials was extracted from ClinicalTrials.gov. Following review of all 165 trials fitting the search criteria only a surprisingly low number of trials adjusted their cox model for additional prognostic covariates, a method which has been shown to lead to significant improvements of effect sizes.
Additionally, our colleagues Laura Schlieker, Markus Waser, Rebecca Freudling and Yesilda Balavarca will be present on site and will participate in a variety of social events, including a welcome reception on Sunday, a networking event on Monday, and the grand gala dinner on Tuesday evening.
We look forward to engaging with the vibrant community at PSI 2024 and hope to see you in Amsterdam!
